Good
Mostly Aligned
Patient Risk:
Low
Summary
Most claims align with the provided label content for indication, general concept of TTR binding/stabilization, and oral administration/dosing forms (tafamidis vs tafamidis meglumine). Minor alignment limitations include lack of label support for 'generally well tolerated' and for mechanistic links beyond what was provided, plus a potentially imprecise framing about generic availability.
Category Scores
Accurate Statements
Vyndaqel (tafamidis) is used for transthyretin amyloid cardiomyopathy (ATTR-CM).
INDICATIONS AND USAGE: VYNDAQEL and VYNDAQAX indicated for cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults.
ATTR-CM is a disease in which abnormal transthyretin protein deposits can damage the heart.
Vyndaqel is prescribed to help slow disease progression in people with ATTR-CM.
INDICATIONS AND USAGE: indicated to reduce cardiovascular mortality and cardiovascular-related hospitalization (label wording does not explicitly state 'slow disease progression' in the provided sections).
Vyndaqel binds to transthyretin (TTR).
Vyndaqel is taken by mouth.
DOSAGE AND ADMINISTRATION: either VYNDAQEL capsules orally once daily.
Vyndaqel and Vyndamax are both tafamidis-based options used in ATTR-CM.
INDICATIONS AND USAGE: VYNDAQEL and VYNDAQAX indicated for treatment of ATTR-CM in adults.
Vyndamax is tafamidis meglumine.
Vyndaqel is tafamidis (free acid).
Availability of generics or alternative versions of Vyndaqel depends on jurisdiction and patent/exclusivity status.
Unsupported Statements
ATTR-CM is a disease in which abnormal transthyretin protein deposits can damage the heart.
The provided FDA label excerpts do not define ATTR-CM pathophysiology or state this deposit mechanism.
Vyndaqel is prescribed to help slow disease progression in people with ATTR-CM.
The provided label excerpts describe reduction in cardiovascular mortality and cardiovascular-related hospitalization, but the provided text does not use the phrase or claim 'slow disease progression.'
Vyndaqel binds to transthyretin (TTR).
No provided label excerpt includes a binding mechanism statement.
Binding to TTR helps stabilize transthyretin.
No provided label excerpt includes the mechanism of stabilization.
Stabilizing TTR reduces the formation of amyloid deposits linked to ATTR-CM.
No provided label excerpt includes this downstream mechanism.
Vyndaqel is generally well tolerated.
No provided label excerpt includes tolerability/impression language or adverse reaction/tolerability statements.
Vyndamax is tafamidis meglumine.
Provided prompt label evidence indicates VYNDAMAX is tafamidis (61 mg) and VYNDAQEL is tafamidis meglumine (80 mg as four 20-mg tafamidis meglumine capsules). This specific mapping is contradicted by the provided dosage text.
Vyndaqel is tafamidis (free acid).
Provided dosage text indicates VYNDAQEL is tafamidis meglumine (80 mg as four 20-mg tafamidis meglumine capsules), not free acid.
Availability of generics or alternative versions of Vyndaqel depends on jurisdiction and patent/exclusivity status.
The provided FDA label excerpts do not address generic availability or patent/exclusivity.
Contradictions
Low
AI Statement
Vyndamax is tafamidis meglumine.
Label Reference
DOSAGE AND ADMINISTRATION — 2.1 Recommended Dosage: VYNDAQEL 80 mg (four 20-mg tafamidis meglumine capsules) orally once daily OR VYNDAMAX 61 mg (one 61-mg tafamidis capsule) orally once daily.
Low
AI Statement
Vyndaqel is tafamidis (free acid).
Label Reference
DOSAGE AND ADMINISTRATION — 2.1 Recommended Dosage: VYNDAQEL 80 mg (four 20-mg tafamidis meglumine capsules) orally once daily.
Important Omissions
Dose-specific details (VYNDAQEL 80 mg once daily as four 20-mg tafamidis meglumine capsules OR VYNDAMAX 61 mg once daily) and non-substitutability on a per mg basis.
Importance:
Moderate
Label-defined outcomes for the indication (reduction of cardiovascular mortality and cardiovascular-related hospitalization) as opposed to 'slowing disease progression.'
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Key safety-critical elements (contraindications, warnings, adverse reactions, monitoring) were not addressed in the AI claims provided, and the only direct product-composition contradictions were about which tafamidis salt corresponds to which product. Missing dose/substitutability details could be clinically relevant, but the prompt’s claims did not include dosing instructions beyond oral use.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Mechanism and tolerability statements are unsupported by the provided label excerpts; product/ingredient mapping statements for VYNDAQEL vs VYNDAMAX contradict the provided dosage wording.
Suggested Improvement
Align product descriptions to the label wording (VYNDAQEL = tafamidis meglumine; VYNDAMAX = tafamidis) and restrict claims to label-supported outcomes (reduce cardiovascular mortality and cardiovascular-related hospitalization). Avoid unsupported mechanistic and tolerability generalizations unless supported by the provided prescribing information text.